id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0013-0046,FDA,FDA-1977-N-0013,Interim Response to GlaxoSmithKline Consumer Healthcare - Letter,Other,Letter(s),2011-07-21T04:00:00Z,2011,7,2011-07-21T04:00:00Z,,2011-07-21T12:31:43Z,,0,0,0900006480ec80bf
FDA-1977-N-0013-0042,FDA,FDA-1977-N-0013,Citizen Petition from GlaxoSmithKline Consumer Healthcare,Other,Citizen Petition,2011-03-24T04:00:00Z,2011,3,2011-03-24T04:00:00Z,,2019-02-05T12:47:52Z,,0,0,0900006480c0c71c
FDA-1977-N-0013-0044,FDA,FDA-1977-N-0013,"Attachment 2 - Synopsis Report, Study Number A4000685 re: Citizen Petition from GlaxoSmithKline Consumer Healthcare",Supporting & Related Material,Background Material,2011-03-24T04:00:00Z,2011,3,,,2019-02-06T16:43:39Z,,0,0,0900006480c0c908
FDA-1977-N-0013-0045,FDA,FDA-1977-N-0013,Acknowledgment Letter from FDA DDM to GlaxoSmithKline Consumer Healthcare,Other,Acknowledgement Letter/Receipt,2011-03-24T04:00:00Z,2011,3,2011-03-24T04:00:00Z,,2019-02-05T13:13:02Z,,0,0,0900006480c0c93a
FDA-1977-N-0013-0043,FDA,FDA-1977-N-0013,"Attachment 1 - Synopsis Report, Study Number A4000684 re: Citizen Petition from GlaxoSmithKline Consumer Healthcare",Supporting & Related Material,Background Material,2011-03-24T04:00:00Z,2011,3,,,2019-02-05T13:00:37Z,,0,0,0900006480c0c905